FDA accepts NDA for Incyte/Novartis drug; NPS snags rights to two GSK programs;

@FierceBiotech: Insmed shares crater as FDA puts a clamp on Ph3 CF study. Report | Follow @FierceBiotech

@JohnCFierce: Sometimes wonder when/if a Big Pharma would do a Valeant, punt early-stage research, pick up good stuff after PoC. Pfizer? | Follow @JohnCFierce

@RyanMFierce: BioClinica 2Q earnings out, service revenue up 8.7% News $BIOC | Follow @RyanMFierce

@MaureenFierce: Which 3 Pharmas are tops for cardiology meds? $PFE is one, according to doctors. Article | Follow @MaureenFierce

> The FDA has accepted Incyte's NDA for its lead compound, ruxolitinib (INCB18424/INC424), a potential treatment for patients with myelofibrosis. The treatment has been developed under a collaboration deal the biotech struck with Novartis. Release

> NPS Pharma has amended its licensing deal with GlaxoSmithKline, snagging the rights to two compounds--SB-423557 and SB-423562--for autosomal dominant hypocalcemia with hypercalciuria, a rare endocrine disorder. Article

> Shares of Ista Pharmaceuticals were depressed by the news that regulators at the FDA don't believe that the company submitted adequate data to support the approval of a larger dose of its eye drug Bromday. Story

> Quintiles named Dr. Jeffrey A. Spaeder as its chief medical and scientific officer. Release

> Scientists believe they have found a marker indicating genetic predisposition to tuberculosis, bringing closer the day when doctors can adjust therapies to individuals based on their genotype. Article

> Embedded in a feature story on diagnostic microchips, Texas CEO magazine makes a compelling case for the reasons behind biomarkers' seeming inability to transfer quickly enough from lab to clinic. Report

> 'Systems biology' could find earliest signs of breast cancer. Story

Pharma News

@FiercePharma: Wockhardt finally unloads nutrition unit, to Danone. French giant also said to be eyeing Pfizer's nutrition biz. Story | Follow @FiercePharma

> Hedge fund swoops in with $38M Amag bid. News

> Government watchdog attacks FDA conflicts plan. More

> Merck, Norvatis top drug approval rankings. Article

> Read Pfizer CEO'slips: No large deals. Story

> Study: Antipsychotic doesn't work for vet's PTSD. Report

Drug Delivery News

> More companies going with prefilled syringes ahead of flu season. Item

> Growth factor delivery method makes long-lasting blood vessels. More

> Pfizer completes sale of Capsugel delivery unit. Report

> OctoPlus tries to get drug-delivery tentacles into generics. Story

> Nanomaterial improves on VEGF for blood-vessel growth. News

> Depomed inks another deal for AcuForm, this time with Ironwood. Article

Medical Device News

> FMD speaks with Cell>Point's David Rollo. Item

> Berlin Heart pediatric offering could soon help US patents. Piece

> Restoration Robotics raises $41M. Story

> BD, Lab21 team on Aspergillus assay. News

> Fresenius buys US competitors. Article

> Ellipse Technologis completes $17.6M Series C financing. More

> Becton Dickson sees strong Q3. Report

And Finally... It's always good to have a sense of humor in the face of illness, but researchers say that laughter may not be the best medicine for COPD. Release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.